Highlights
- Imugene’s CF33 oncolytic virus technology will be featured at one of the most prestigious immunotherapy events.
- The technology has been accepted for a Trial-in-Progress Poster.
- The event in the US during early November, would open opportunities for discussion and networking with oncology community members.
ASX-listed biotechnology group Imugene Limited (ASX: IMU) shared that its CF33 oncolytic virus technology will be featured at the Society for Immunotherapy of Cancer (SITC) annual meeting. The event will be held in San Diego, the US, on 1-5 November 2023.
The prestigious immunotherapy event, SITC 2023, showcases advanced research presentations by a number of experts, oral and poster abstract presentations. Also, the event creates opportunities for discussion and networking with the experts in the oncology community.
Data Source: Company update
About Imugene
Imugene is focused on developing new and novel immunotherapies. Supported by a leading team of international cancer experts, the clinical stage immuno-oncology company is advancing its product pipeline comprising multiple immunotherapy B-cell vaccine candidates and the oncolytic virotherapy (CF33).
IMU shares traded at AU$0.096 apiece at the time of writing on 3 August 2023.